Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Trial finds prunes do not outperform calcium and vitamin D for male bone density

11

Jun 2026

Trial finds prunes do not outperform calcium and vitamin D for male bone density

A one-year randomized trial found that daily prune supplementation did not improve total or lumbar spine bone mineral density in older men susceptible to, or with, osteopenia. Although some bone turnover biomarkers differed between prune and control groups, these changes did not translate into measurable bone density benefits beyond calcium and vitamin D3 supplementation.

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

11

Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

FDA accepts immunotherapy drug for review in colon cancer treatment

11

Jun 2026

FDA accepts immunotherapy drug for review in colon cancer treatment

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

Study: Employer points systems drive workers to show up sick

11

Jun 2026

Study: Employer points systems drive workers to show up sick

A new study finds that employer points systems, which penalize workers for absences regardless of the reason, are strongly associated with presenteeism, the practice of showing up to work while sick, and that these systems undermine the public health benefits of paid sick leave laws even in jurisdictions where such protections are on the books.

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

11

Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.